Ignite Creation Date:
2024-05-05 @ 5:11 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00400738
Status:
COMPLETED
Last Update Posted:
2012-04-05
First Post:
2006-11-09
Brief Title:
The Pharmacokinetics of Double Boosted Protease Inhibitors in Antiretroviral-naive HIV-1 Infected Patients
Sponsor:
The HIV Netherlands Australia Thailand Research Collaboration
Organization:
The HIV Netherlands Australia Thailand Research Collaboration
Study Overview
Official Title:
Pharmacokinetics of and Rate of HIV-1 RNA Decline in ARV-naive HIV-1 Infected Patients Treated With Low- or Standard-dose Saquinavir HGC Invirase and LopinavirRitonavir Kaletra
Status:
COMPLETED
Status Verified Date:
2012-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Treatment with only protease inhibitors might benefit HIV patients Laboratory data have shown that the combination of saquinavir with lopinavir and ritonavir may a good regimen This study will explore this idea
Detailed Description:
Treatment with only protease inhibitors might benefit HIV patients who experience problems with the other antiretrovirals drugs classes Another reason to only use protease inhibitors is that the remaining classes are spared This leaves the option to use these classes in the future for instance in cases of drug resistance Laboratory data have shown that the combination of saquinavir with lopinavir and ritonavir may a good regimen This study will explore this idea
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None